These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 2066456

  • 1. Intravenous lisuride in the treatment of the neuroleptic malignant syndrome.
    Sczesni B, Bittkau S, von Baumgarten F, von Schröder J, Suchy I, Przuntek H.
    J Clin Psychopharmacol; 1991 Jun; 11(3):185-8. PubMed ID: 2066456
    [Abstract] [Full Text] [Related]

  • 2. Intravenous administration of lisuride in the treatment of neuroleptic malignant syndrome.
    de Mari M, Lamberti P, Simone F, Iliceto G, Federico F, Ferrari E.
    Funct Neurol; 1991 Jun; 6(3):285-8. PubMed ID: 1683852
    [Abstract] [Full Text] [Related]

  • 3. Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion.
    Rodriguez ME, Luquin MR, Lera G, Delgado G, Salazar JM, Obeso JA.
    Mov Disord; 1990 Jun; 5(2):170-2. PubMed ID: 2325680
    [Abstract] [Full Text] [Related]

  • 4. [Neuroleptic malignant syndrome].
    Sczesni B, Schröder J, Becker H, Przuntek H.
    Wien Klin Wochenschr; 1991 Jun; 103(1):1-7. PubMed ID: 1673041
    [Abstract] [Full Text] [Related]

  • 5. Successful treatment of a complicated case of neuroleptic malignant syndrome.
    Lappa A, Podestà M, Capelli O, Castagna A, Di Placido G, Alampi D, Semeraro F.
    Intensive Care Med; 2002 Jul; 28(7):976-7. PubMed ID: 12122539
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [A study of neuroleptic malignant syndrome in the presenium and senium].
    Suzuki I, Honma H, Watanabe N, Matsubara S, Koyama T.
    Seishin Shinkeigaku Zasshi; 1998 Jul; 100(6):387-97. PubMed ID: 9745353
    [Abstract] [Full Text] [Related]

  • 8. The treatment of neuroleptic malignant syndrome using dantrolene sodium.
    Tsutsumi Y, Yamamoto K, Matsuura S, Hata S, Sakai M, Shirakura K.
    Psychiatry Clin Neurosci; 1998 Aug; 52(4):433-8. PubMed ID: 9766694
    [Abstract] [Full Text] [Related]

  • 9. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
    Ozen ME, Yumru M, Savas HA, Cansel N, Herken H.
    World J Biol Psychiatry; 2007 Aug; 8(1):42-4. PubMed ID: 17366349
    [Abstract] [Full Text] [Related]

  • 10. [Neuroleptic malignant syndrome. Case reports].
    Berardi D, Troia M, Veronesi L, Ferrari G.
    Minerva Psichiatr; 1994 Dec; 35(4):199-219. PubMed ID: 7861943
    [Abstract] [Full Text] [Related]

  • 11. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F, Ruggieri S, Brughitta G, Agnoli A.
    J Neural Transm Suppl; 1986 Dec; 22():209-18. PubMed ID: 3465872
    [Abstract] [Full Text] [Related]

  • 12. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Khaldi S, Kornreich C, Choubani Z, Gourevitch R.
    Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460
    [Abstract] [Full Text] [Related]

  • 13. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
    Benes H.
    Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
    [Abstract] [Full Text] [Related]

  • 14. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S, Stocchi F, Carta A, Bravi D, Bragoni M, Giorgi L, Agnoli A.
    Mov Disord; 1988 Jan; 3(4):313-9. PubMed ID: 3211176
    [Abstract] [Full Text] [Related]

  • 15. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.
    Bittkau S, Przuntek H.
    J Neural Transm Suppl; 1988 Jan; 27():35-54. PubMed ID: 3165438
    [Abstract] [Full Text] [Related]

  • 16. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J, Luquin MR, Obeso JA.
    Mov Disord; 1990 Jan; 5(3):260-2. PubMed ID: 2388647
    [Abstract] [Full Text] [Related]

  • 17. Neuroleptic malignant syndrome: a review and report of six cases.
    Kasantikul D, Kanchanatawan B.
    J Med Assoc Thai; 2006 Dec; 89(12):2155-60. PubMed ID: 17214072
    [Abstract] [Full Text] [Related]

  • 18. Neuroleptic malignant syndrome in Mexico.
    Montoya A, Ocampo M, Torres-Ruiz A.
    Can J Clin Pharmacol; 2003 Dec; 10(3):111-3. PubMed ID: 14506509
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis and treatment of neuroleptic malignant syndrome.
    Guerrero RM, Shifrar KA.
    Clin Pharm; 1988 Sep; 7(9):697-701. PubMed ID: 3240662
    [Abstract] [Full Text] [Related]

  • 20. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome.
    Lee JW.
    Ann Clin Psychiatry; 2007 Sep; 19(1):9-16. PubMed ID: 17453656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.